Latest Breaking News On - Patients with locally advanced or metastatic ros1 positive non small cell lung cancer - Page 1 : comparemela.com

Misako Nagasaka, MD, discusses key findings from the phase 1/2 TRIDENT-1 trial of repotrectinib in patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.

United statesIrvine schoolMisako nagasakaUniversity of californiaDivision of hematology oncologyIrvine school of medicineIrvine school of medicineTrident 1 trialPatients with locally advanced or metastatic ros1 positive non small cell lung cancer